ProPhase Labs (NASDAQ:PRPH) Upgraded to Hold at Wall Street Zen

ProPhase Labs (NASDAQ:PRPH) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of ProPhase Labs in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

ProPhase Labs Stock Performance

PRPH stock opened at $0.52 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The business has a 50-day moving average price of $0.28 and a 200 day moving average price of $0.36. The company has a market capitalization of $2.40 million, a P/E ratio of -1.33 and a beta of -0.66. ProPhase Labs has a 1-year low of $0.50 and a 1-year high of $9.35.

ProPhase Labs (NASDAQ:PRPH) last issued its earnings results on Wednesday, November 19th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $0.88 million for the quarter, compared to the consensus estimate of $5.69 million. ProPhase Labs had a negative return on equity of 482.05% and a negative net margin of 825.01%. As a group, equities research analysts forecast that ProPhase Labs will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PRPH. XTX Topco Ltd bought a new position in shares of ProPhase Labs during the 2nd quarter worth approximately $40,000. Apollon Wealth Management LLC purchased a new position in ProPhase Labs in the third quarter worth $84,000. Josh Arnold Investment Consultant LLC purchased a new position in ProPhase Labs in the first quarter worth $100,000. Accretive Wealth Partners LLC acquired a new position in shares of ProPhase Labs during the third quarter worth $114,000. Finally, Susquehanna International Group LLP lifted its holdings in shares of ProPhase Labs by 290.1% during the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares during the last quarter. Hedge funds and other institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.